World Meningococcal Vaccines Market - Opportunities and Forecasts, 2017 - 2023

Meningococcal vaccines are used to treat meningitis caused by bacterium N. meningitidis. Previously there were no precautionary measures available to avoid meningitis. Antibiotics along with nutrient supplements were used to treat this disease after infection was confirmed. However, with the advent of meningococcal vaccine, meningitis could be prevented. The global market for vaccines was estimated to be $24 billion in 2013. The increasing incidence of meningitis across the world is the major driving force for this market. Rising awareness level of diseases and their vaccines also drives the market for meningococcal vaccines. The maintenance of cold chain for the delivery of vaccines leads to rise in cost of vaccination, which serves as the major limiting factor for this market. World Health Organization is promoting strategies for prevention of meningitis and is hoping to introduce this vaccine in 26 countries of African region, which are suffering from meningitis and they hope to achieve it by 2016. This would provide growth opportunities in this market.

Meningococcal vaccines types market analysis

The meningococcal vaccine market can be classified based on its types into quadrivalent, bivalent, serogroup A, serogroup B and serogroup X. Polysaccharide and conjugate are two types of quadrivalent vaccine. A new vaccine named Baxsero, a conjugate vaccine has been a huge success in prevention of meningitis.

Meningococcal vaccines geography market analysis

This market is classified based on its geography into North America, Europe, Asia-Pacific and rest of the world (RoW). North American market is the highest revenue generating region for this vaccine.

Competitive Landscape

The major players in this market are Sanofi S.A., Novartis International, GlaxoSmithKline, Pfizer Inc., Serum Institute of India Ltd., JN-International Medical Corporation, Nuron Biotech, Baxter International and Biomed Pvt. Ltd. Novartis International with its new product is dominating the market. It has come up with a new vaccine named Baxsero, which has proved to be very beneficial in preventing meningitis. Pfizer Inc. is planning to target adolescent with their vaccine.

High level analysis

The report analyses global meningococcal vaccines market with the help of Porter’s five forces model. Porter’s model helps in analyzing the market players, new entrants in the market and the strategies adopted by them. In this market, the unavailability of substitutes result in high bargaining power of suppliers and low bargaining power of buyers. The meningococcal vaccine is a capital-intensive market; therefore, it is difficult for new entrants to enter the business. Market dynamics is analyzed for the benefit of the stakeholders.

KEY BENEFITS

Estimations are made by considering current market trends, and future potential investment for analysis period 2014-2020
Benefits of meningococcal vaccines in prevention of meningitis are explained in the report
In-depth analysis of market growth drivers, restraints and opportunities is done to assist the stakeholders in understanding the various factors affecting this market
Macro environmental analysis of the market is done using Porter’s five forces model to analyze the various components of this industry.
The market is analyzed based on its type and geography to help the stakeholders in understanding the market and its trends.

KEY MARKETS SEGMENTS

Market by Types

Quadrivalent vaccines
Bivalent vaccines
Serogroup A
Serogroup B
Serogroup X

Market by Geography

North America
Europe
Asia-pacific
RoW



* This report will be delivered in 12 Business Days. *